Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 2/20 | 0.41 |
| ▸ | CTSK | P43235 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | F10 | P00742 | 6/20 | 0.40 |
| ▸ | PRSS1 | P07477 | 4/20 | 0.40 |
| ▸ | F2 | P00734 | 3/20 | 0.40 |
| ▸ | CTSL | P07711 | 1/20 | 0.40 |
| ▸ | BCAT2 | O15382 | 1/20 | 0.40 |
| ▸ | F7 | P08709 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17177645 | 0.88 | F10 (0.43) | CTSSCTSKF10PRSS1F2 | |
| SCHEMBL6156498 | 0.88 | CTSS (0.41) | CTSSCTSKF10PRSS1F2 | |
| SCHEMBL2945634 | 0.88 | MME (0.48) | CTSSCTSKCTSLATMMEN1 | |
| SCHEMBL1360814 | 0.85 | MMP1 (0.45) | — | |
| SCHEMBL1361680 | 0.83 | GPR88 (0.44) | CTSSCTSKPKMSMN1; SMN2NPSR1 | |
| SCHEMBL1362522 | 0.82 | TACR1 (0.55) | CTSSCTSKF10PRSS1F2 | |
| SCHEMBL17177760 | 0.81 | BCAT2 (0.44) | CTSSCTSKCYP1A2CYP2D6PKM | |
| SCHEMBL1363688 | 0.81 | CNR2 (0.46) | CYP1A2CYP2D6PKMSMN1; SMN2NPSR1 | |
| SCHEMBL1360839 | 0.81 | TACR1 (0.41) | CTSSCTSKCTSLATMMEN1 | |
| SCHEMBL1362244 | 0.81 | CYP3A4 (0.47) | CTSSCTSKF10PRSS1CTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1501813-B1 | Benzothiadiazepine derivatives, processes for their preparation and pharmaceutical compositions containing them | ALBIREO AB (SE) | 2013-08-14 | — | — | EP | disclosed |
| US-8067584-B2 | Benzothiazepine derivatives | ALBIREO AB (SE) | 2011-11-29 | — | — | US | disclosed |
| EP-1430040-B1 | BENZOTHIAZEPINE DERIVATIVES | ALBIREO AB (SE) | 2009-08-05 | — | — | EP | disclosed |
| US-7238684-B2 | Benzothiadiazepine derivatives, processes for their preparation and pharmaceutical compositions containing them | ASTRAZENECA AB (SE) | 2007-07-03 | — | — | US | disclosed |
| US-7192946-B2 | Benzothiazepine derivatives | ASTRAZENECA AB (SE) | 2007-03-20 | — | — | US | disclosed |
| US-20060094884-A1 | Benzothiazepine and benzothiepine derivatives | ALBIREO AB (SE) | 2006-05-04 | — | — | US | disclosed |
| EP-1597245-A1 | BENZOTHIAZEPINE AND BENZOTHIEPINE DERIVATIVES | AstraZeneca AB (SE) | 2005-11-23 | — | — | EP | disclosed |
| US-20050143368-A1 | Chemical compounds | ALBIREO AB (SE) | 2005-06-30 | — | — | US | disclosed |
| EP-1501813-A2 | BENZOTHIADIAZEPINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Astrazeneca AB (SE) | 2005-02-02 | — | — | EP | disclosed |
| US-20040254160-A1 | Benzothiazepine derivatives | ELOBIX AB (SE) | 2004-12-16 | — | — | US | disclosed |
| WO-2004076430-A1 | BENZOTHIAZEPINE AND BENZOTHIEPINE DERIVATIVES | ASTRAZENECA AB (SE) | 2004-09-10 | — | — | WO | disclosed |
| WO-2003091232-A2 | BENZOTHIADIAZEPINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | ASTRAZENECA AB (SE) | 2003-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050143368-A1 | Chemical compounds | SLC10A2, SLC10A1, ABCB11 | CTSS 3448/4885CTSK 3505/4885CYP1A2 293/4885 |
| US-20040254160-A1 | Benzothiazepine derivatives | SLC10A2, SLC10A1, ABCB11 | CTSS 2430/4885CTSK 2668/4885CYP1A2 172/4885 |
| US-20060094884-A1 | Benzothiazepine and benzothiepine derivatives | SLC10A2, SLC10A1, ABCB11 | CTSS 3193/4885CTSK 3174/4885CYP1A2 203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.